Gene Set

	Gene Set			
C5 -		ΙC(Δ)	p-value	FDR
ABDULRAHMAN_KIDNEY_CANCER_VHL_DN -		0.648(0.009)	2.62e-06	1.67e-05
KRIEG_HYPOXIA_NOT_VIA_KDM3A -		0.590(0.010)	2.62e-06	1.67e-05
GROSS_HYPOXIA_VIA_HIF1A_ONLY -		0.583(0.011)	2.62e-06	1.67e-05
TRACEY_RESISTANCE_TO_IFNA2 -		0.579(0.008)	2.62e-06	1.67e-05
SU_KIDNEY -		0.577(0.010)	2.62e-06	1.67e-05
TRACEY_RESISTANCE_TO_IFNA2_UP -		0.573(0.007)	2.62e-06	1.67e-05
REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS -		0.572(0.008)	2.62e-06	1.67e-05
BIOCARTA_INTRINSIC_PATHWAY -		0.571(0.010)	2.62e-06	1.67e-05
REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS		0.571(0.008)	2.62e-06	1.67e-05
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP -		0.568(0.007)	2.62e-06	1.67e-05
SMID_BREAST_CANCER_NORMAL_LIKE_DN -		0.567(0.007)	2.62e-06	1.67e-05
CROMER_METASTASIS -		0.566(0.010)	2.62e-06	1.67e-05
GROGER_EMT_DN -		0.566(0.163)	2.62e-06	1.67e-05
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP -		0.565(0.016)	2.62e-06	1.67e-05
P53_DN.V1_DN -		0.556(0.007)	2.62e-06	1.67e-05
AIGNER_ZEB1_TARGETS -		0.554(0.105)	2.62e-06	1.67e-05
JIANG_HYPOXIA_CANCER -		0.554(0.009)	2.62e-06	1.67e-05
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING -		0.554(0.008)	2.62e-06	1.67e-05
BIOCARTA_AMI_PATHWAY -		0.553(0.009)	2.62e-06	1.67e-05
KANG_IMMORTALIZED_BY_TERT -		0.552(0.009)	2.62e-06	1.67e-05
MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS -		-0.480(0.009)	2.62e-06	1.26e-04
OXFORD_RALA_AND_RALB_TARGETS -		-0.483(0.007)	2.62e-06	1.26e-04
INAMURA_LUNG_CANCER_SCC -		-0.497(0.010)	2.62e-06	1.26e-04
KRAS.300_UP.V1 -		-0.498(0.010)	2.62e-06	1.26e-04
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS -		-0.500(0.131)	2.62e-06	1.26e-04
BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE -		-0.505(0.056)	2.62e-06	1.26e-04
ESC_J1_UP_EARLY.V1 -		-0.505(0.008)	2.62e-06	1.26e-04
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL -		-0.512(0.008)	2.62e-06	1.26e-04
P53_DN.V1 -		-0.513(0.008)	2.62e-06	1.26e-04
LANDIS_BREAST_CANCER_PROGRESSION_UP -		-0.516(0.149)	2.62e-06	1.26e-04
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN -		-0.519(0.059)	2.62e-06	1.26e-04
SMID_BREAST_CANCER_NORMAL_LIKE -		-0.521(0.008)	2.62e-06	1.26e-04
CROMER_METASTASIS_DN -		-0.529(0.141)	2.62e-06	1.26e-04
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP -		-0.531(0.136)	2.62e-06	1.26e-04
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP -		-0.543(0.007)	2.62e-06	1.26e-04
JAEGER_METASTASIS_DN -		-0.548(0.060)	2.62e-06	1.26e-04
TAUBE_EMT_DN -		-0.557(0.153)	2.62e-06	1.26e-04
OSADA_ASCL1_TARGETS -		-0.567(0.007)	2.62e-06	1.26e-04
COLDREN_GEFITINIB_RESISTANCE_DN -		-0.572(0.130)	2.62e-06	1.26e-04
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP -		-0.584(0.067)	2.62e-06	1.26e-04